GlassScriptPhysician profile
Unknown Lianna
NPI 1881415214
$2,501.64
in general payments reported to CMS, 2019-2025
14 companies · $2,367 in 2025
The $2,367 reported for 2025 was more than what 97% of Primary Care providers received nationally (typical 2025 total: $170).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2024: $135 · 2025: $2,367.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,502.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,501.64 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $838.27 | 2025 | |
| Ardelyx, INC. | $481.29 | 2025 | Ibsrela |
| Phathom Pharmaceuticals, INC. | $448.57 | 2024-2025 | Voquezna |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $291.84 | 2025 | Xifaxan |
| Madrigal Pharmaceuticals | $130.95 | 2025 | Rezdiffra |
| Pfizer INC. | $125.00 | 2025 | |
| Gilead Sciences, INC. | $28.12 | 2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $27.91 | 2025 | Entyvio |
| Aimmune Therapeutics, INC. | $27.34 | 2025 | Vowst |
| Qol Medical, LLC | $25.62 | 2025 | Sucraid |
| Janssen Biotech, INC. | $25.05 | 2025 | Tremfya |
| Vivus LLC | $17.92 | 2025 | Pancreaze |
| Genzyme Corporation | $17.11 | 2025 | |
| Ipsen Biopharmaceuticals, INC | $16.65 | 2025 | Iqirvo |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Unknown Lianna listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.